Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas

Summary

The purpose of this study is to assess the safety and tolerability of CVac, an investigational cell therapy, in patients with resected stage I or II adenocarcinoma of the pancreas who have completed surgery with or without front-line chemotherapy or radiation therapy. After confirmation of non-measurable disease patients will undergo leukapheresis for manufacture of the study agent.

Timeline

Start

2015-02

Primary completion

2015-03

Completion

2015-03

Outcome

Outcome not reported

Stopped: “The trial has been terminated per Sponsor direction due to longer than expected clinical and regulatory approvals.”

Drugs

Indications